Quiros Juan Jose Chacon Sells 7,751 Shares of Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 7,751 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $70.48, for a total transaction of $546,290.48. Following the transaction, the director directly owned 1,032,504 shares of the company’s stock, valued at approximately $72,770,881.92. This represents a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The stock was sold at an average price of $70.78, for a total transaction of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The stock was sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Up 1.1%

Establishment Labs stock opened at $70.99 on Wednesday. The firm has a fifty day moving average price of $65.43 and a two-hundred day moving average price of $66.22. The firm has a market cap of $2.09 billion, a price-to-earnings ratio of -40.80 and a beta of 1.12. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a fifty-two week low of $32.25 and a fifty-two week high of $83.31.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. During the same quarter last year, the company earned ($1.19) earnings per share. The firm’s revenue was up 45.2% on a year-over-year basis. As a group, analysts forecast that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors have recently bought and sold shares of ESTA. Goldman Sachs Group Inc. raised its position in Establishment Labs by 117.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Viking Global Investors LP bought a new position in Establishment Labs in the 2nd quarter valued at $14,669,000. Bamco Inc. NY grew its stake in shares of Establishment Labs by 30.2% during the third quarter. Bamco Inc. NY now owns 1,181,824 shares of the company’s stock valued at $48,443,000 after purchasing an additional 274,287 shares during the last quarter. Woodson Capital Management LP grew its stake in shares of Establishment Labs by 113.3% during the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after purchasing an additional 255,000 shares during the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $9,050,000. Institutional investors own 72.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Friday, March 27th. Needham & Company LLC increased their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Citigroup reduced their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Stephens increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group increased their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.